Furthermore, other mutations (in NRAS, BRAF, PIK3CA, PTEN amplifications, HER2/MET, and right-sided primary CRC) have also been associated with reduced response rates, demonstrating the complexity of CRC’s underlying biology and the need for a more nuanced approach to patient stratification [150,151]. This evidence concerns the gene NRAS and colorectal carcinoma.